Share on

Europe Anti-neoplastic Agents Market Research Report – Segmented By Product Type, End User & Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: March, 2023
ID: 8048
Pages: 145
Formats: report pdf report excel report power bi report ppt

The size of the European Anti-neoplastic Agents Market is forecasted to hike at a robust CAGR between 2022 to 2027.

Increasing investment in cancer research by multinational corporations due to rising cancer prevalence is predicted to drive the European market for anti-neoplastic drugs over the forecast period. The anti-neoplastic agent market is expected to develop as cancer incidences increase and the senior population grows. Consumers' lifestyles are changing, which means the danger of cancer is rising. This has piqued the interest of numerous pharmaceutical companies to enter the anti-neoplastic agent industry, increasing in the antineoplastic agent market. Manufacturers of anti-neoplastic medicines have a tremendous opportunity due to several technological advancements in customized medicine. The chemotherapeutic agent sector is likely to lead the market due to simple access to pharmaceuticals. In contrast, the immunotherapeutic agent segment is expected to develop significantly due to the growing acceptability of biological therapy due to fewer side effects.

Furthermore, the market's expected rise is related to rising cancer cases and the desire for cost-effective medicines over the forecasted timeframe. One of the most common reasons for such events is changes in an individual's DNA, resulting in reduced gene activity and, eventually, Cancer. Furthermore, as the number of people afflicted with cancer rises, the Antineoplastic Therapy Market is likely to develop in the next few years as new and improved technologies are discovered. These medications are used in radiotherapies, surgeries, hormone therapies, and other targeted therapies combined with other drugs, which drives market trends. The antineoplastic agents market is also driven by stringent regulations about the safety of drug development procedures and the effectiveness of quality control and quality assurance rules that regulate the pharmaceutical and related industries in several industrialized nations.

Physicians and researchers face a significant challenge in meeting unmet requirements in treating malignant neoplasms as the number of patients grows. Antineoplastic medicines are frequently employed as first-line therapy for cancer treatment and in conjunction with surgery or radiation therapy. However, the varied nature of cancer and the high development cost of anti-neoplastic drugs restrict the market's growth. Anti-neoplastic drugs are costly due to the significant expenses associated with their development. As a result, some customers cannot afford these agents, which is expected to hamper the growth of the antineoplastic agents market in the European region.

This research report on the European Anti-neoplastic Agents market has been segmented and sub-segmented into the following categories.

By Product:

  • Chemotherapeutic Agents
  • Biological Agents   
  • Personalized Medicine  

By End Users:

  • Hospitals 
  • Clinics        
  • Cancer Rehabilitation Centers            
  • Ambulatory Surgical Centers           

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

In the global market for anti-neoplastic agents, Europe is predicted to have the second most significant market share during the forecast period. According to Cancer Research UK, 605 persons per 100,000 were diagnosed with cancer in 2013. The antineoplastic market is predicted to increase rapidly as new cases of neoplasms are reported in the region. The demand for cost-effective medicines to treat neoplasms is projected to drive the Antineoplastic Agents Market in the near future. In addition, the Antineoplastic Therapy Market is being driven by an increase in the flow of funds into research and development by national and international organizations such as the WHO.

KEY MARKET PLAYERS:

Some of the major companies dominating the market by their products and services include Aspen Global Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Pvt. Ltd., Merc & Co., Inc., Pfize Inc., Hoffmann-La Roche Ltd., Amgen Inc., Bristol-Myers Squibb Company, Baxter Healthcare Corporation, Boehringer Ingelheim GmbH, Accord Healthcare, Inc., Genentech, Inc., Lundbeck LLC, and AbbVie Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample